Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Resistance to HIV-1 entry inhibitors.

W C Olson1, P J Maddon

  • 1Progenics Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA. olson@progenics.com

Current Drug Targets. Infectious Disorders
|February 3, 2004
PubMed
Summary

Resistance testing is crucial for managing human immunodeficiency virus type 1 (HIV-1) infection. New HIV-1 entry inhibitors, including attachment, coreceptor, and fusion inhibitors, offer distinct resistance profiles and complementary therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibodies for HIV treatment and prevention: window of opportunity?

Current topics in microbiology and immunology·2007
Same author

IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro.

Cancer gene therapy·2006
Same author

Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes.

Journal of virology·2001
Same author

Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

Journal of virology·2001
Same author

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.

The Journal of infectious diseases·2001
Same author

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.

Journal of virology·2001

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • Resistance testing is standard for HIV-1 protease and reverse transcriptase inhibitors.
  • HIV-1 entry inhibitors represent an emerging class of antiretroviral therapy.
  • Understanding viral resistance is key for developing new HIV-1 treatments.

Purpose of the Study:

  • To review the role of resistance testing in the context of emerging HIV-1 entry inhibitors.
  • To discuss the distinct resistance profiles of attachment, coreceptor, and fusion inhibitors.
  • To highlight the complementary nature of these novel therapeutic classes.

Main Methods:

  • Review of current clinical trial data for HIV-1 entry inhibitors.
  • Analysis of resistance determinants and evolution for distinct inhibitor classes.
  • Examination of parallel advances in resistance-testing technologies.

Main Results:

  • HIV-1 entry inhibitors encompass attachment, coreceptor, and fusion inhibitors.
  • Each class has shown promise in clinical trials.
  • Attachment, coreceptor, and fusion inhibitors exhibit distinct resistance profiles.

Conclusions:

  • Resistance testing is vital for the optimal deployment of new HIV-1 entry inhibitor therapies.
  • These inhibitors offer complementary therapeutic options.
  • Distinct resistance profiles necessitate tailored treatment strategies.

Related Experiment Videos